Glucose Reduction by Early Acarbose Treatment in Basal Insulin (GREAN)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Acarbose (Glucobay, BAYG5421)
Voglibose (Basen)
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Oral Hypoglycemic Agent
Eligibility Criteria
Inclusion Criteria:
- Aged 18-79 years
Type 2 diabetes inadequately controlled with insulin glargine alone or in combination with metformin
- Diagnosed of type 2 diabetes for at least 6 months prior to screening
- Treated with tolerable, stable dose of insulin glargine and/or metformin for at least 3 months prior to screening
- HbA1C > 7.0 and </= 10.0% at screening
Exclusion Criteria:
- Type 1 diabetes patients
- Myocardial infarction, unstable angina or coronary artery bypass surgery within previous 6 months
- Clinical evidence of active liver disease, or serum ALT or AST 3 times the upper limit of the normal (ULN) range
- Serum creatinine >/= 1.5 mg/dl for males, >/= 1.4 mg/dl for females
- Active proliferative diabetic retinopathy
- Any other anti-diabetic medications except insulin glargine and metformin within 4 weeks prior to study entry
- Gastrointestinal diseases that are likely to be associated with abnormal intestinal motility or altered absorption of nutrients (e.g. gastroparesis, malabsorption syndrome, chronic diarrhea states, enteropathies, inflammatory bowel disease, partial intestinal obstruction, and large hernias)
- Galactose intolerance
- Pregnancy
- Delivery, abortion, or lactation within less than three cycles before the start of treatment
- No use of contraceptive in childbearing aged. Women of childbearing potential must agree to use adequate contraception (barrier method of birth control) since signing of the informed consent form until at least 30 days after the last study drug administration.
- Hypersensitivity to the active substances or any of gradient of the study drug ingredients
- Treatment with any medication including corticosteroid or herb medication that can affect blood glucose level in the 3 months prior to study entry
- Any disease or condition that in the opinion of the investigator may interfere with completion of the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Arm 1
Arm 2
Arm Description
Outcomes
Primary Outcome Measures
Glycosylated hemoglobin (HbA1c)
Secondary Outcome Measures
Self monitoring blood glucose concentration
Fasting blood glucose concentration
Blood concentration of triglyceride
Blood concentration of low density lipoprotein
Blood concentration of total cholesterol
Blood concentration of high density lipoprotein
Blood concentration of apolipoprotein A-1
Blood concentration of apolipoprotein B
Blood concentration of Glucagon-like peptide-1 (GLP-1)
Body weight, Body Mass Index(BMI)
High Sensitivity C-reactive protein (hs-CRP)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00970528
Brief Title
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
Acronym
GREAN
Official Title
A Randomized, Parallel Group, Open-Label, Active-Controlled Study Comparing Acarbose With Voglibose in Patients Who Are Inadequately Controlled With Insulin Glargine Alone or in Combination With Metformin Based on Glycemic Control
Study Type
Interventional
2. Study Status
Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
November 2009 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bayer
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of acarbose in comparison with voglibose in type 2 diabetic patients whose blood glucose levels were inadequately controlled with insulin glargine alone or in combination with metformin.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Oral Hypoglycemic Agent
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
124 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arm 1
Arm Type
Experimental
Arm Title
Arm 2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Acarbose (Glucobay, BAYG5421)
Intervention Description
uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
Intervention Type
Drug
Intervention Name(s)
Voglibose (Basen)
Intervention Description
uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
Primary Outcome Measure Information:
Title
Glycosylated hemoglobin (HbA1c)
Time Frame
Change from baseline to week 24, at week -2, 0, 8 and 24
Secondary Outcome Measure Information:
Title
Self monitoring blood glucose concentration
Time Frame
6 points for 2 days prior to each visit (at week 0, 4, 8, 16 and 24)
Title
Fasting blood glucose concentration
Time Frame
At week -2, 0, 4, 8, 16 and 24
Title
Blood concentration of triglyceride
Time Frame
At week -2 and 24
Title
Blood concentration of low density lipoprotein
Time Frame
At week -2 and 24
Title
Blood concentration of total cholesterol
Time Frame
At week -2 and 24
Title
Blood concentration of high density lipoprotein
Time Frame
At week -2 and 24
Title
Blood concentration of apolipoprotein A-1
Time Frame
At week -2 and 24
Title
Blood concentration of apolipoprotein B
Time Frame
At week -2 and 24
Title
Blood concentration of Glucagon-like peptide-1 (GLP-1)
Time Frame
At week -0 and 24
Title
Body weight, Body Mass Index(BMI)
Time Frame
At week -2, 0, 4, 8, 16 and 24
Title
High Sensitivity C-reactive protein (hs-CRP)
Time Frame
At week -2 and 24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged 18-79 years
Type 2 diabetes inadequately controlled with insulin glargine alone or in combination with metformin
Diagnosed of type 2 diabetes for at least 6 months prior to screening
Treated with tolerable, stable dose of insulin glargine and/or metformin for at least 3 months prior to screening
HbA1C > 7.0 and </= 10.0% at screening
Exclusion Criteria:
Type 1 diabetes patients
Myocardial infarction, unstable angina or coronary artery bypass surgery within previous 6 months
Clinical evidence of active liver disease, or serum ALT or AST 3 times the upper limit of the normal (ULN) range
Serum creatinine >/= 1.5 mg/dl for males, >/= 1.4 mg/dl for females
Active proliferative diabetic retinopathy
Any other anti-diabetic medications except insulin glargine and metformin within 4 weeks prior to study entry
Gastrointestinal diseases that are likely to be associated with abnormal intestinal motility or altered absorption of nutrients (e.g. gastroparesis, malabsorption syndrome, chronic diarrhea states, enteropathies, inflammatory bowel disease, partial intestinal obstruction, and large hernias)
Galactose intolerance
Pregnancy
Delivery, abortion, or lactation within less than three cycles before the start of treatment
No use of contraceptive in childbearing aged. Women of childbearing potential must agree to use adequate contraception (barrier method of birth control) since signing of the informed consent form until at least 30 days after the last study drug administration.
Hypersensitivity to the active substances or any of gradient of the study drug ingredients
Treatment with any medication including corticosteroid or herb medication that can affect blood glucose level in the 3 months prior to study entry
Any disease or condition that in the opinion of the investigator may interfere with completion of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bayer Study Director
Organizational Affiliation
Bayer
Official's Role
Study Director
Facility Information:
City
Wonju-si
State/Province
Gang''weondo
ZIP/Postal Code
220-701
Country
Korea, Republic of
City
Busan
State/Province
Korea
ZIP/Postal Code
602-714
Country
Korea, Republic of
City
Gyeonggi-do
State/Province
Korea
ZIP/Postal Code
463-500
Country
Korea, Republic of
City
Gyeonggi-do
State/Province
Korea
ZIP/Postal Code
471-701
Country
Korea, Republic of
City
Pusan
State/Province
Korea
ZIP/Postal Code
602-739
Country
Korea, Republic of
City
Seoul
State/Province
Korea
ZIP/Postal Code
150-713
Country
Korea, Republic of
City
Daegu
ZIP/Postal Code
705-717
Country
Korea, Republic of
City
Jeonju-si
ZIP/Postal Code
456-712
Country
Korea, Republic of
City
Seongbuk-gu Seoul
ZIP/Postal Code
136-705
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
134-701
Country
Korea, Republic of
City
Seoul
ZIP/Postal Code
135-710
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
24431911
Citation
Lee MY, Choi DS, Lee MK, Lee HW, Park TS, Kim DM, Chung CH, Kim DK, Kim IJ, Jang HC, Park YS, Kwon HS, Lee SH, Shin HK. Comparison of acarbose and voglibose in diabetes patients who are inadequately controlled with basal insulin treatment: randomized, parallel, open-label, active-controlled study. J Korean Med Sci. 2014 Jan;29(1):90-7. doi: 10.3346/jkms.2014.29.1.90. Epub 2013 Dec 26.
Results Reference
derived
Learn more about this trial
Glucose Reduction by Early Acarbose Treatment in Basal Insulin
We'll reach out to this number within 24 hrs